Jeremy Bender Sells 15,459 Shares of Day One Biopharmaceuticals (NASDAQ:DAWN) Stock

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) CEO Jeremy Bender sold 15,459 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $179,324.40. Following the completion of the sale, the chief executive officer directly owned 204,603 shares in the company, valued at approximately $2,373,394.80. This trade represents a 7.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Day One Biopharmaceuticals Trading Down 2.7%

Shares of DAWN stock traded down $0.32 on Wednesday, reaching $11.56. 1,478,926 shares of the stock were exchanged, compared to its average volume of 2,543,632. The company has a market capitalization of $1.19 billion, a price-to-earnings ratio of -7.61 and a beta of -1.26. The business’s 50 day moving average price is $10.28 and its 200 day moving average price is $8.55. Day One Biopharmaceuticals, Inc. has a twelve month low of $5.64 and a twelve month high of $13.20.

Analysts Set New Price Targets

Several equities research analysts recently commented on DAWN shares. Piper Sandler boosted their price target on shares of Day One Biopharmaceuticals from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Needham & Company LLC reissued a “buy” rating and issued a $16.00 target price on shares of Day One Biopharmaceuticals in a report on Monday, November 24th. TD Cowen assumed coverage on Day One Biopharmaceuticals in a research note on Tuesday, January 13th. They set a “buy” rating and a $34.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of Day One Biopharmaceuticals in a research note on Monday, November 24th. Finally, JPMorgan Chase & Co. raised their target price on shares of Day One Biopharmaceuticals from $26.00 to $27.00 and gave the stock an “overweight” rating in a research report on Friday, November 7th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Day One Biopharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $25.71.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 6,282,376 shares of the company’s stock worth $58,552,000 after acquiring an additional 101,047 shares during the period. Vestal Point Capital LP raised its holdings in Day One Biopharmaceuticals by 94.4% during the fourth quarter. Vestal Point Capital LP now owns 5,200,000 shares of the company’s stock worth $48,464,000 after purchasing an additional 2,525,000 shares in the last quarter. Deerfield Management Company L.P. lifted its position in Day One Biopharmaceuticals by 26.4% in the third quarter. Deerfield Management Company L.P. now owns 4,705,413 shares of the company’s stock valued at $33,173,000 after purchasing an additional 982,282 shares during the period. State Street Corp boosted its holdings in Day One Biopharmaceuticals by 32.4% in the 4th quarter. State Street Corp now owns 4,289,566 shares of the company’s stock valued at $39,979,000 after purchasing an additional 1,049,122 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in Day One Biopharmaceuticals by 2.0% during the 2nd quarter. Franklin Resources Inc. now owns 4,097,625 shares of the company’s stock worth $26,635,000 after purchasing an additional 79,255 shares during the period. 87.95% of the stock is owned by institutional investors and hedge funds.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.